Lanthanide Complexes for Protein Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the crystal structure of biological macromolecules, such as proteins, face significant challenges including low success rates in protein purification and crystallization, with only 1.8% of cloned proteins being structurally characterized, and existing phasing agents like lanthanides being unstable or requiring modification of the protein structure.
Innovation Solution
Development of cationic lanthanide complexes with specific ligands that provide a stable, water-soluble, and luminescent phasing agent capable of facilitating crystallization and structural determination without modifying the protein, acting as both a nucleating and crystallizing agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional crystallization methods are used, then the process is simple, but the success rate is low (only 1.8% of cloned proteins are structurally characterized)
Solution Approach 1:
The patent introduces lanthanide complexes as intermediary substances that mediate between the protein and the crystallization process. These complexes bind to proteins and facilitate crystal formation, acting as a bridge that improves reliability without requiring complex genetic engineering or covalent bonding.
Solution Approach 2:
The patent changes the chemical parameters of the crystallization medium by adding lanthanide complexes. This alters the physical-chemical environment to favor crystallization, transforming the crystallization process from an empirical trial-and-error approach to a more controlled and reliable method.
2Reliability
If existing phasing agents like lanthanides are used, then structural determination is enabled, but the agents are unstable or require protein modification
Solution Approach 1:
The patent uses lanthanide complexes as intermediary phasing agents that do not require covalent bonding with the protein. These complexes temporarily associate with proteins during crystallization and can be removed afterward, providing stable phase information without permanent protein modification.
Solution Approach 2:
The patent extracts the phasing function from the protein structure itself and provides it through external lanthanide complexes. This separates the phasing requirement from the protein, allowing the protein to remain unmodified while still achieving the necessary phase information for structural determination.
3Reliability
If empirical trial-and-error approaches are used for crystallization, then the method is easy to implement, but the success rate remains low and resource consumption is high
Solution Approach 1:
The patent systematically changes the chemical parameters of crystallization by introducing lanthanide complexes at defined concentrations and conditions. This transforms the empirical approach into a more systematic method based on understood chemical interactions, reducing the time and resources needed for screening.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cationic lanthanide complexes enhance the crystallization process and structural data acquisition, increasing the success rate of obtaining crystals and structural information for biological macromolecules, while being stable in commercial crystallization media and not requiring genetic engineering or covalent bonding with the protein.
Implementation Method 1
determining the structure of proteins to understand the relationships between their structure and their functions... crystallography allows faster determination of structures... X-ray diffraction
Implementation Method 2
The crystallization processes of biological macromolecules... nucleation and crystal growth... The crystallizing agent induces a modification of the solubility and therefore of the position on the diagram as a function of time
Implementation Method 3
new luminescent derivatives of DPA... functional derivatives of DPA... luminescent phasing agents in the literature
Data Source
Figure 1~2
Figure 3
Figure 4~8
AI summary
The invention relates to cationic complexes made up of a lanthanide ion Ln3+ and a ligand of formula (I) with X, Y and R1 as defined in claim 1, and to the salts thereof with an anion, the solvates and hydrates thereof; with the exception of cationic complexes made up of a lanthanide ion Ln3+ and a ligand of one of formulae (1.1) or (1.4) as defined in claim 1, and the salts, solvates and hydrates thereof. The invention also relates to the use of such a complex or of a cationic complex made up of a lanthanide ion Ln3+ and a ligand of formula (1.1) or (1.4) as defined in claim 1, or of one of the salts thereof with an anion, the solvates or hydrates thereof, as an aid to the crystallisation of a biological macromolecule, as well as to crystallisation methods and methods for analysing or determining the structure of a biological macromolecule.